Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer.
Lopès A, Billard E, Casse AH, Villéger R, Veziant J, Roche G, Carrier G, Sauvanet P, Briat A, Pagès F, Naimi S, Pezet D, Barnich N, Dumas B, Bonnet M.
Lopès A, et al. Among authors: carrier g.
Int J Cancer. 2020 Jun 1;146(11):3147-3159. doi: 10.1002/ijc.32920. Epub 2020 Mar 10.
Int J Cancer. 2020.
PMID: 32037530
Free article.